mortality/aging
• doxycycline-treated mice exhibit a median survival of 7 to 8 weeks
|
neoplasm
• withdrawal of doxycycline leads to complete tumor regression
• ALK kinase inhibitor is a more effective therapy than chemotherapy in doxycycline-treated mice
|
• doxycycline-treated mice develop lung tumorigenesis with a latency of less than 10 days
• however, withdrawal of doxycycline leads to complete tumor regression
|
• adenocarcinomas predominantly bronchioloalveolar carcinoma with occasional pleural space and airway invasion by an acinar component in doxycycline-treated mice
|
growth/size/body
weight loss
(
J:166724
)
• in tumor-bearing, doxycycline-treated mice in the first 4 weeks
|
respiratory system
N |
• untreated mice exhibit normal lung histology
|
• doxycycline-treated mice develop lung tumorigenesis with a latency of less than 10 days
• however, withdrawal of doxycycline leads to complete tumor regression
|
• adenocarcinomas predominantly bronchioloalveolar carcinoma with occasional pleural space and airway invasion by an acinar component in doxycycline-treated mice
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
lung cancer | DOID:1324 |
OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210 |
J:166724 | |
lung non-small cell carcinoma | DOID:3908 | J:166724 |